Dendritic cells (DCs) are bone-marrow-derived cells that populate all lymphoid organs as well as nearly all non-lymphoid organs. Although DCs display a heterogeneous group of cells that represent differences in origin, anatomic, location, cell surface phenotype, and function. They are powerful antigen-presenting cells that have a critical role in the initial activation of naïve cells and the recall of memory immune responses.

Immature DCs reside as sentinels in non lymphoid organs; they are high adapted for the uptake of antigen via receptor- and nonreceptor-mediated mechanisms and readily degrade antigens in endocytic vesicles to produce antigen peptides capable of binding to Human Leukocyte Antigens class II.

Upon maturation with pathogens, activated T Lymphocytes and/or inflammatory signals such as TNFα, IL-1β, or lipopolysaccharides (LPS), immature DCs underwent genetic reprogramming leading to mature DCs characterized by high expression of HLA class II molecules absence of lineage markers such as CD14 (monocytes), CD3 (T cells), CD19, CD20 (B cells), CD56 (NK cells), high level expression of costimulatory molecules CD83, CD86, CD80, CD40, and adhesion molecules such as CD11a, CD11c. Mature DCs also acquire ability to migrate which is regulated by expression of chemokines and chemokines receptors CCR7.

These chemokines guide mature DCs to lymphatic vessels and to secondary lymphoid organs.

**DC Subsets.** In human DCs comprise at least three distinct subsets.

(i) Langerhans cells LC and interstitial DCs belonging to the myeloid lineage and plasmacytoid DCs originate from a lymphoid precursor (Table 1).

(ii) LCs are localized in the layers of the epidermis in the skin and other mucosal areas, whereas interstitial DCs are present in the dermis of the skin and in most other organs.

(iii) Human plasmacytoid DCs are found in the T-cell zones of lymphoid organs (Table 1).

There seem to be several pathways to generate DCs.
### Table 1

| Postulated lineage | Lymphoid DC | Myeloid DC |
|--------------------|-------------|------------|
| DC subtype         | Plasmacytoid | Interstitial | Langerhans cell |
| Fully differentiated DC | CD11c<sup>-</sup> CD123<sup>+</sup> | CD11c<sup>-</sup> CD123<sup>-</sup> | CD11c<sup>-</sup> CD123<sup>-</sup> |
|                    | CD11b<sup>-</sup> CD13<sup>-</sup> CD33<sup>-</sup> | CD11b<sup>-</sup> CD13<sup>-</sup> CD33<sup>-</sup> | CD11b<sup>-</sup> CD13<sup>-</sup> CD33<sup>-</sup> |
|                    | CD1a<sup>-</sup> | CD1a<sup>-</sup> | CD1a<sup>-</sup> |

| Localization       | T-cell zones of lymphoid organs | T-cell zones of lymphoid organs immature cells in peripheral tissues | T-cell zones of lymphoid organs immature cells in epithelia |
|--------------------|---------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|

| Function            | (i) Mannose receptor-mediated endocytosis | (ii) IL-12 | (iii) IL-10 | (iv) IFNγ | (v) CD4<sup>+</sup> T-cell priming |
|--------------------|------------------------------------------|-----------|------------|----------|-------------------------------|
|                    | —                                       | ++ +      |            | —        | ++ +                          |
|                    |                                          | ++ +      | ++ +       | —        | —                             |
|                    |                                          | —         | ++ +       | —        | —                             |
|                    |                                          | ++ +      | ++ +       | —        | ++ +                          |

### Generation of dendritic cells

Blood monocytes give rise to DCs when cultured with the appropriate cytokines. DCs progenitors are also present in bone marrow. CD34<sup>+</sup> subsets of haematopoietic progenitors give rise to all blood cells and DCs.

In vitro human DCs can be generated from CD34<sup>+</sup> bone marrow and peripheral blood progenitor’s cells: after culture with different cytokine combinations including GM-CSF, TNFα, CD40L. Alternatively, DC can be derived from CD14<sup>+</sup> peripheral blood adhering monocytes.

PBMCs are obtained by cytapheresis isolated by Ficoll Hypaque density gradient and cultured with GM-CSF and rhIL-4. At the end of 5-days culture, immature DCs are harvested. Maturation was induced by adding proinflammatory stimuli such as TNFα, LPS, or IL-1β or on ligation of CD40. At the last 48 h of culture on day 7, mature DCs were harvested (Figure 1).

Upon maturation, DCs display high expression of costimulatory, presenting and accessory molecules, uptake molecules were decreased. Induction of allogeneic T-cell proliferation in MLR by DCs has been associated with DC maturation including production of proinflammatory cytokines such as TNFα, IL-12, IFNγ. Alternatively, DCs produce low levels of IL-10, anti-inflammatory cytokine.

Recently, it has been reported that upon activation DCs exhibit transient production of IL-2 and express IL-2Rα, a property that appears to be related to their capacity to initiate immune responses. Besides, the ability of DCs to produce IL-2 after encountering inflammatory stimuli provides the
first crucial signals for the activation of naïve T cells. The kinetics of IL-2 production by DCs are compatible with the appearance of HLA class II and class I peptides at the cell surface of DCs, so IL-2 appears to be one of the key molecules conferring unique T-cell stimulating capacity on DCs.

Dendritic cells (DCs) play a key role in the initiation and regulation of both the adaptive and the innate immune responses [1–5]. DC progenitors leave the bone marrow (BM) and give rise to circulating precursors. They differentiate into immature DCs that are distributed throughout the peripheral tissues and mucosa and act as sentinels of the immune system [3, 4]. They are characterized by a high capacity for antigen uptake and processing [3]. In response to inflammatory stimuli, immature DCs rapidly undergo a complete genetic reprogramming. During the first twenty-four hours, DCs experience all the transcription modifications necessary to progress from immature to mature cells that are characterized by a high capacity for antigen presentation and T-cell priming [5, 6]. The mature DCs then migrate to the secondary lymphoid organs where they interact with T cells. This complex “maturation” process involves not only the upregulation of costimulatory surface proteins and the optimization of antigen presentation capacities, but also the production of cytokines and chemokines [4–6] that profoundly influences the outcome of the T-cell response. The signals in DC involved in each of these phenomena are not completely understood.

The signals delivered by DC are believed to direct the T-cell response into either a Th1, Th2, or nonpolarized T-cell response [7, 8], but they can also drive the differentiation of regulatory T cells involved in self-tolerance [2–9]. Thus, the extraordinary versatility of dendritic cells has recently become apparent. Although much is known about the cytokines produced by T cells and the T-cell-associated transcription factors that determine the T-helper polarization, the early “decision-making mechanisms” which result in a given type of immune response are poorly understood and possibly are based on specific cytokine and chemokine synthesis profiles by DC. This area remains a subject of intense investigations.

In addition to affecting adaptive immunity, the cytokine synthesis profiles of DCs might also influence their capacity to activate cells involved in innate immunity such as NK cells [10, 11].

It has recently been demonstrated that mouse and human DCs can both produce IL-2 after activation with several stimuli [12]. The expression and the function of the IL2 receptor on DCs have been rarely studied. One study in mice showed IL-2Ra expression on DCs but they could not ascribe any role to its expression [13]. Thus, the role of IL2 signalling in DC function remains poorly defined. It was, therefore, relevant to study how this pathway influenced the DC cytokine secretion profile and their ability to activate CD4+ T cells.

In the present study, we report that CD25 expression was strongly upregulated on DCs by several maturation signals such as LPS. In addition, we demonstrated that IL2 signalling in DCs upregulated both IL-12 and IFNγ production but decreased IL10 synthesis. We also found that LPS-matured DCs produced IL2. Taken together, these results suggest that IL-2 actively contributes to DC activation through an autocrine pathway. Finally, our results indicate that the IL2 pathway in DC is involved in the development of T-helper priming ability and in the upregulation of surface markers characteristic of a “mature” phenotype. Antagonizing IL2 signalling in DCs may therefore influence the immune response in vivo. These actions of anti-CD25 antibodies on DC functions may contribute to their action in vivo on several immunological disorders such as autoimmune diseases [14, 15] and prevention of acute human allograft rejection [16].

In conclusion, our data suggested that the level of IL2 signalling in DCs regulate their capacity to efficiently prime the T-helper immune response. Therefore, targeting this pathway ex vivo might be useful for protocols in cellular therapy to orientate DC toward a tolerogenic profile (by using anti-CD25 treated DC) able to promote Treg differentiation or at the opposite to promote or restore immunity against tumors (by using IL2-treated DCs).

References

[1] C. Reis E Sousa, “Activation of dendritic cells: translating innate into adaptive immunity,” Current Opinion in Immunology, vol. 16, no. 1, pp. 21–25, 2004.

[2] R. M. Steinman, D. Hawiger, and M. C. Nussenzweig, “Tolerogenic dendritic cells,” Annual Review of Immunology, vol. 21, pp. 685–711, 2003.

[3] J. Banchereau, F. Briere, C. Caux et al., “Immunobiology of dendritic cells,” Annual Review of Immunology, vol. 18, pp. 767–811, 2000.

[4] J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998.

[5] R. M. Steinman, B. Gutschinov, M. D. Witmer, and M. C. Nussenzweig, “Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice,” Journal of Experimental Medicine, vol. 157, no. 2, pp. 613–627, 1983.

[6] F. Granucci, C. Vizzardelli, N. Pavelka et al., “Inducible IL-2 production by dendritic cells revealed by global gene expression analysis,” Nature Immunology, vol. 2, no. 9, pp. 882–888, 2001.

[7] S. E. Macatonia, N. A. Hosken, M. Litton et al., “Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells,” Journal of Immunology, vol. 154, no. 10, pp. 5071–5079, 1995.

[8] M. Moser and K. M. Murphy, “Dendritic cell regulation of Th1-Th2 development,” Nature Immunology, vol. 1, no. 3, pp. 199–205, 2000.

[9] R. M. Steinman and M. C. Nussenzweig, “Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 351–358, 2002.

[10] N. C. Fernandez, A. Lozier, C. Flamet et al., “Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo,” Nature Medicine, vol. 5, no. 4, pp. 405–411, 1999.

[11] F. Granucci, I. Zanoni, N. Pavelka et al., “A contribution of mouse dendritic cell-derived IL-2 for NK cell activation,” Journal of Experimental Medicine, vol. 200, no. 3, pp. 287–295, 2004.
[12] S. Feau, V. Facchinetti, F. Granucci et al., “Dendritic cell-derived IL-2 production is regulated by IL-15 in humans and in mice,” *Blood*, vol. 105, no. 2, pp. 697–702, 2005.

[13] V. Kronin, D. Vremec, and K. Shortman, “Does the IL-2 receptor α chain induced on dendritic cells have a biological function?” *International Immunology*, vol. 10, no. 2, pp. 237–240, 1998.

[14] B. Bielekova, M. Catalfamo, S. Reichert-Scrivner et al., “Regulatory CD56 natural killer cells mediate immunomodulatory effects of IL-2Ra-targeted therapy (daclizumab) in multiple sclerosis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 15, pp. 5941–5946, 2006.

[15] B. Bielekova, N. Richert, T. Howard et al., “Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 23, pp. 8705–8708, 2004.

[16] F. Vincenti, R. Kirkman, S. Light et al., “Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation,” *New England Journal of Medicine*, vol. 338, no. 3, pp. 161–165, 1998.
Submit your manuscripts at http://www.hindawi.com